← ANALYST RATINGS · TIPRANKS
Phreesia (PHR): analyst forecast and price target
Analyst consensus
Moderate Buy5 Buy2 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $14.00, the highest $19.00, the lowest $11.00. The average is +28.0% from the last price of $10.94.
Analyst ratings 20
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $10.00 → $11.00+10.0% | Hold | +0.5% | Reiterated | 09.10.26on TipRanks Oct 11 21:15 | +0.8%next day +0.2% · 5 days +3.2% | ↗ |
| Ryan Halsted★★★★★★★★★★#3317 · hits 60% · avg +9.0% | RBC Capital | $19.00 | Buy | +73.7% | Reiterated | 06.10.26on TipRanks 21:45 | +2.7%next day +1.9% · 5 days +2.2% | ↗ |
| Ryan Daniels★★★★★★★★★★#2878 · hits 48% · avg +5.8% | William Blair | — | Buy | — | Reiterated | 02.10.26on TipRanks 16:45 | +2.3%next day −1.7% · 5 days +3.9% | ↗ |
| AI xAi Medical - Healthcare Information ServicesxAI Grok-3 | TipRanks - xAI | $12.00 → $10.50−12.5% | Hold | −4.0% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| AI DeepSeek Medical - Healthcare Information ServicesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $10.50−12.5% | Hold | −4.0% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| AI OpenAI Medical - Healthcare Information ServicesOpenAI 5.2 | TipRanks - OpenAI | $12.00 → $10.50−12.5% | Hold | −4.0% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| AI Anthropic Medical - Healthcare Information ServicesAnthropic Opus-4.5 | TipRanks - Anthropic | $12.00 → $10.50−12.5% | Hold | −4.0% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| AI Google Medical - Healthcare Information ServicesGemini 3-pro | TipRanks - Google | $12.00 → $10.50−12.5% | Hold | −4.0% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| AI PerPlexity Medical - Healthcare Information ServicesPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.00−8.3% | Buy | +0.5% | Reiterated | 25.09.26on TipRanks 02:05 | — | |
| Parker Snure★★★★★★★★★★#8410 · hits 67% · avg +1.7% | Raymond James | $12.00 | Hold | +9.7% | Downgrade | 08.09.26on TipRanks 06:50 | −6.0%next day +1.6% · 5 days +2.4% | ↗ |
| Joseph Vruwink★★★★★★★★★★#1159 · hits 59% · avg +7.8% | Robert W. Baird | $10.00 → $11.00+10.0% | Hold | +0.5% | Reiterated | 04.09.26on TipRanks 07:05 | −1.1%next day −6.0% · 5 days −3.5% | ↗ |
| Clark Wright★★★★★★★★★★#6630 · hits 49% · avg +1.6% | D.A. Davidson | $13.00 | Buy | +18.8% | Reiterated | 04.09.26on TipRanks Sep 3 12:25 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Eugene Mannheimer★★★★★★★★★★#3417 · hits 51% · avg +6.8% | Freedom Capital Markets | $14.00 | Buy | +28.0% | Reiterated | 03.09.26on TipRanks Sep 27 04:50 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Jailendra Singh★★★★★★★★★★#12131 · hits 43% · avg −6.4% | Truist Financial | — | Hold | — | Reiterated | 03.09.26on TipRanks 08:15 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Richard Close★★★★★★★★★★#1081 · hits 49% · avg +10.0% | Canaccord Genuity | $16.00 | Buy | +46.3% | Reiterated | 03.09.26on TipRanks 06:55 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Stan Berenshteyn★★★★★★★★★★#11485 · hits 50% · avg −5.0% | Wells Fargo | $9.00 → $10.00+11.1% | Hold | −8.6% | Assigned | 03.09.26on TipRanks 06:35 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Ryan MacDonald★★★★★★★★★★#12366 · hits 37% · avg −11.1% | Needham | $14.00 | Buy | +28.0% | Reiterated | 03.09.26on TipRanks 05:05 | −7.4%next day −1.1% · 5 days −6.0% | ↗ |
| Alexei Gogolev★★★★★★★★★★#2483 · hits 54% · avg +6.0% | J.P. Morgan | $14.00 | Hold | +28.0% | Reiterated | 25.06.26on TipRanks 07:18 | −4.9%next day +11.0% · 5 days +18.4% | ↗ |
| Sean Dodge★★★★★★★★★★#11980 · hits 43% · avg −4.3% | BMO Capital | $14.00 | Buy | +28.0% | Reiterated | 22.06.26on TipRanks 08:25 | −4.6%next day +4.0% · 5 days +15.8% | ↗ |
| Jessica Tassan★★★★★★★★★★#11189 · hits 43% · avg −3.3% | Piper Sandler | $23.00 → $12.00−47.8% | Hold | +9.7% | Downgrade | 28.05.26on TipRanks 14:25 | +3.0%next day +4.1% · 5 days +2.2% | ↗ |
| Unknown Analyst | Jefferies | $20.00 | Buy | +82.8% | Reiterated | 28.05.26on TipRanks 10:50 | +3.0%next day +4.1% · 5 days +2.2% | ↗ |
| Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% | Citi | $10.00 → $12.00+20.0% | Hold | +9.7% | Reiterated | 28.05.26on TipRanks 06:50 | +3.0%next day +4.1% · 5 days +2.2% | ↗ |
| Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% | KeyBanc | $15.00 → $12.00−20.0% | Buy | +9.7% | Assigned | 13.04.26on TipRanks 06:50 | +5.2%next day −0.8% · 5 days +6.9% | ↗ |
| Aaron Kimson★★★★★★★★★★#4446 · hits 54% · avg +5.1% | Citizens JMP | — | Hold | — | Downgrade | 01.04.26on TipRanks 05:15 | −0.5%next day −0.4% · 5 days −7.5% | ↗ |
| Jeffrey Garro★★★★★★★★★★#12266 · hits 30% · avg −24.4% | Stephens | $20.00 | Buy | +82.8% | Reiterated | 31.03.26on TipRanks 07:30 | −29.5%next day −0.5% · 5 days +0.5% | ↗ |
| Steven Valiquette★★★★★★★★★★#8240 · hits 53% · avg 0.0% | Mizuho Securities | $22.00 → $19.00−13.6% | Buy | +73.7% | Reiterated | 24.03.26on TipRanks 07:16 | −4.1%next day −0.6% · 5 days −25.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Phreesia
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.22 at a price of $10.33 (+28.0%); now: $13.33 at $10.94 (+21.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 3 | 2 | 0 | 1 | 2 |
| Buy | 4 | 3 | 2 | 1 | 6 | 7 |
| Hold | 4 | 4 | 3 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 09.12.26 (Q3 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.12 (from $0.05 to $0.24). Last quarter: $0.03.
Sales
Next quarter’s sales estimate — $128M (from $126M to $132M). Last quarter: $129M.
Best top-analyst consensus in the sector · Healthcare
About Phreesia
- CEO: Chaim Indig
- Employees: 1,789
- 1521 Concord Pike, Wilmington, DE, 19803, US
- www.phreesia.com
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
Data from the stock’s TipRanks forecast page, read 3 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗